peginterferon alfa 2a (Pegasys)
Jump to navigation
Jump to search
Introduction
Polyethylene-glycol modified interferon alfa 2a.
Tradename: Pegasys
Indications
- treatment of chronic hepatitis B[2]
- treatment of hepatitis C
Dosage
- weekly SC injections (48 weeks)[2]
- 1.5 ug/kg/week[4]
- 180 ug/week
Pharmacokinetics
- longer 1/2 life than unmodified IFN-alfa 2a may result in better antiviral activity
Monitor
- liver function tests (serum ALT, serum bilirubin) baseline, 4 weeks, then periodically
- in clinical studies, LFTs were monitored at weeks 1, 2, 4, 6, & 8, then every 4-6 weeks or more frequently if abnormal[5]
Adverse effects
- influenza-like syndrome (fatigue, headache, fever)[7]
- depression, insomnia, irritability[7]
- relatively common
- treatment with escitalopram diminishes depression associated with interferon alfa 2A[6]
- neutropenia, thrombocytopenia, anemia
- autoimmune thyroiditis[7]
- see interferon alfa 2A
Laboratory
- IFNL3 variation rs12979860 predicts response to PEG-interferon-alpha[8]
More general terms
Additional terms
Components
References
- ↑ Journal Watch 21(2):14, 2001 Zeuzem et al N Engl J Med 343:1666, 2000 Heathcote et al N Engl J Med 343:1673, 2000
- ↑ Jump up to: 2.0 2.1 2.2 Journal Watch 24(21):162-63, 2004 Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004 Sep 16;351(12):1206-17. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15371578
- ↑ Department of Veterans Affairs, VA National Formulary
- ↑ Jump up to: 4.0 4.1 Ghany MG et al AASLD PRACTICE GUIDELINES Diagnosis, Management, and Treatment of Hepatitis C: An Update American Association for the Study Liver Diseases (AASLD) 2009, Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/hep.22759 http://www.aasld.org/practiceguidelines/Documents/AASLD_PG--diagnosis_of_HEP_C_2009.pdf
- ↑ Jump up to: 5.0 5.1 Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Liver Function Test Scheduling Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260704&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Jump up to: 6.0 6.1 Schaefer M et al Escitalopram for the Prevention of Peginterferon- alpha-2a-Associated Depression in Hepatitis C Virus- Infected Patients Without Previous Psychiatric Disease: A Randomized Trial. Annals of Internal Medicine, July 17, 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22801672 <Internet> http://annals.org/article.aspx?articleid=1216554
- ↑ Jump up to: 7.0 7.1 7.2 7.3 Medical Knowledge Self Assessment Program (MKSAP) 16 American College of Physicians, Philadelphia 2012
- ↑ Jump up to: 8.0 8.1 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline information for boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin, telaprevir and IFNL3. https://www.pharmgkb.org/guideline/PA166110235